Literature DB >> 12892538

Weight gain in the treatment of mood disorders.

Louis J Aronne1, Karen R Segal.   

Abstract

Overweight and obesity have become an urgent public health problem in the United States: approximately 61% of the adult population (97 million adults) are overweight or obese, where overweight is defined as a body mass index (BMI) >/= 25 and obesity is defined as a BMI >/= 30. Overweight and obesity increase the risk for developing many serious chronic diseases such as cardiovascular disease, type 2 diabetes, hypertension, dyslipidemia, and certain cancers. Increased morbidity due to obesity-related disorders begins within the normal weight range. Weight gain in adulthood per se, even in individuals who are normal weight, has deleterious health effects. Medications, particularly those commonly used in psychiatry and neurology, are a significant iatrogenic source of overweight and obesity. The weight gain potential of prescription medications should be considered in order to enhance patient compliance and reduce the risk of metabolic sequelae of weight gain. This article provides an overview of the weight-gain potential of several classes of drugs commonly used in psychiatric practice and considerations for clinicians in prescribing these medications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12892538

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  29 in total

Review 1.  Use of psychopharmacological agents for functional gastrointestinal disorders.

Authors:  R E Clouse; P J Lustman
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

2.  Bidirectional association between depression and type 2 diabetes mellitus in women.

Authors:  An Pan; Michel Lucas; Qi Sun; Rob M van Dam; Oscar H Franco; JoAnn E Manson; Walter C Willett; Alberto Ascherio; Frank B Hu
Journal:  Arch Intern Med       Date:  2010-11-22

3.  Investigation of antidepressant medication usage after bariatric surgery.

Authors:  Julie L Cunningham; Cory C Merrell; Michael Sarr; Kristin J Somers; Donald McAlpine; Michael Reese; Susanna R Stevens; Matthew M Clark
Journal:  Obes Surg       Date:  2012-04       Impact factor: 4.129

Review 4.  Pediatric obesity: etiology and treatment.

Authors:  Melissa K Crocker; Jack A Yanovski
Journal:  Pediatr Clin North Am       Date:  2011-10       Impact factor: 3.278

5.  Associations of self-reported anxiety symptoms with health-related quality of life and health behaviors.

Authors:  Tara W Strine; Daniel P Chapman; Rosemarie Kobau; Lina Balluz
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-06       Impact factor: 4.328

Review 6.  Drug-Induced Hyperglycaemia and Diabetes.

Authors:  Neila Fathallah; Raoudha Slim; Sofien Larif; Houssem Hmouda; Chaker Ben Salem
Journal:  Drug Saf       Date:  2015-12       Impact factor: 5.606

Review 7.  Ten putative contributors to the obesity epidemic.

Authors:  Emily J McAllister; Nikhil V Dhurandhar; Scott W Keith; Louis J Aronne; Jamie Barger; Monica Baskin; Ruth M Benca; Joseph Biggio; Mary M Boggiano; Joe C Eisenmann; Mai Elobeid; Kevin R Fontaine; Peter Gluckman; Erin C Hanlon; Peter Katzmarzyk; Angelo Pietrobelli; David T Redden; Douglas M Ruden; Chenxi Wang; Robert A Waterland; Suzanne M Wright; David B Allison
Journal:  Crit Rev Food Sci Nutr       Date:  2009-11       Impact factor: 11.176

8.  Antidepressant use before and after the diagnosis of type 2 diabetes: a longitudinal modeling study.

Authors:  Mika Kivimäki; Adam G Tabák; Debbie A Lawlor; G David Batty; Archana Singh-Manoux; Markus Jokela; Marianna Virtanen; Paula Salo; Tuula Oksanen; Jaana Pentti; Daniel R Witte; Jussi Vahtera
Journal:  Diabetes Care       Date:  2010-04-05       Impact factor: 17.152

Review 9.  Pediatric obesity: etiology and treatment.

Authors:  Melissa K Crocker; Jack A Yanovski
Journal:  Endocrinol Metab Clin North Am       Date:  2009-09       Impact factor: 4.741

10.  Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program.

Authors:  Richard R Rubin; Yong Ma; David G Marrero; Mark Peyrot; Elizabeth L Barrett-Connor; Steven E Kahn; Steven M Haffner; David W Price; William C Knowler
Journal:  Diabetes Care       Date:  2007-12-10       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.